Keywords: Gilead Sciences, Financial results, Third-quarter 2012, HIV drugs
Gilead beats forecasts, posting 14% rise in third-quarter 2012 sales
Article | 24 October 2012
US antiviral drugs giant Gilead Sciences (Nasdaq: GILD) reported results for the third quarter of 2012, with revenues up 14% to $2.43 billion. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
